“David is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliant’s development,” said
“I am excited to be joining the Pliant board and supporting an accomplished group of board members and a strong leadership team to help guide the company’s mission of delivering innovative and potential transformative treatments to patients,” said
In addition to Pliant,
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, and Facebook.
Investor Contact:
Vice President, Investor Relations and Corporate Communications
ir@pliantrx.com
Media Contact:
cambria.fuqua@canalecomm.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/95826a4d-80dc-482a-aab1-c8684bfa48e5
Dr. David Pyott , Director, Pliant Therapeutics Inc.
Dr. Pyott joins the Pliant Board of Directors with more than 30 years of executive leadership and management experience within the global pharmaceutical industry.
2021 GlobeNewswire, Inc., source